CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- ScaleMarket cap is $1.3B, above the global median of $1.18B
- PositionCurrent ratio is 1.23×, lower than 95% of its Medical Devices peers (median 2.86×)
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
8.70BCNY1.30B · vs all stocks (USD)
Trailing P/E
62.52xvs Medical Devices peers
Revenue (TTM)
4.93BCNY736.06M · vs all stocks (USD)
Profit Margin
2.70%vs Medical Devices peers
Beta
-0.1220xvs all stocks
52-Week Change
-22.16%vs all stocks
Market Capitalization
8.70BCNY1.30B · vs all stocks (USD)
Enterprise Value
8.60BCNY1.28B · vs all stocks (USD)
Trailing P/E
62.52xvs Medical Devices peers
Forward P/E
18.61xvs Medical Devices peers
Price to Sales (TTM)
1.76xvs Medical Devices peers
Price to Book (MRQ)
2.70xvs Medical Devices peers
Enterprise to Revenue
1.74xvs Medical Devices peers
Enterprise to EBITDA
19.36xvs Medical Devices peers
Gross Margin
53.85%vs Medical Devices peers
Profit Margin
2.70%vs Medical Devices peers
Operating Margin
11.61%vs Medical Devices peers
Return on Assets (TTM)
3.12%vs Medical Devices peers
Return on Equity (TTM)
1.86%vs Medical Devices peers
Revenue (TTM)
4.93BCNY736.06M · vs all stocks (USD)
Revenue per Share (TTM)
9.08CNYUpdated Sep 20, 2026Quarterly Revenue Growth
6.20%vs Medical Devices peers
Gross Profit (TTM)
2.40BCNY358.75M · vs all stocks (USD)
EBITDA (TTM)
514.09MCNY76.71M · vs all stocks (USD)
Net Income (TTM)
133.33MCNY19.90M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
13.90%vs Medical Devices peers
Operating Cash Flow (TTM)
569.27MCNY84.95M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
374.86MCNY55.94M · vs all stocks (USD)
5-Year Average Dividend Yield
0.88%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Minority Interest (Equity)
331.32MCNYFY2025 · Dec 31, 2025Revenue
4.66BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
2.39BCNYFY2025 · Dec 31, 2025Gross Profit
2.27BCNYFY2025 · Dec 31, 2025Operating Income
292.65MCNY43.67M · vs all stocks (USD)
Pre-tax Income
74.05MCNYFY2025 · Dec 31, 2025Income Tax Expense
51.98MCNYFY2025 · Dec 31, 2025Net Income
22.08MCNYFY2025 · Dec 31, 2025EBIT
112.94MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
504.94MCNYFY2025 · Dec 31, 2025Research & Development
274.63MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
970.46MCNYFY2025 · Dec 31, 2025Other Operating Expenses
45.93MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
21.56MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
38.88MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.1685CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.1685CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
549.84MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
549.84MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
22.08MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
70.57MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
37.40MCNYFY2025 · Dec 31, 2025Free Cash Flow
-161.38MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
770.87MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
22.08MCNYFY2025 · Dec 31, 2025Other Non-cash Items
47.32MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
92.67MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-124.66MCNYFY2025 · Dec 31, 2025Capital Expenditures
-198.78MCNYFY2025 · Dec 31, 2025Net Acquisitions
122.97KCNYFY2025 · Dec 31, 2025Sale of Investments
36.03MCNYFY2025 · Dec 31, 2025Other Investing Activity
-131.26MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-293.89MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
421.74MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-442.57MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-135.11MCNYFY2025 · Dec 31, 2025Other Financing Charges
-218.10MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-374.03MCNYFY2025 · Dec 31, 2025Shares Outstanding
556.85MSharesUpdated Sep 20, 2026Float Shares
248.52MSharesUpdated Sep 20, 2026% Held by Insiders
54.49%vs all stocks
% Held by Institutions
4.88%vs all stocks
Total Cash (MRQ)
1.02BCNY151.65M · vs all stocks (USD)
Total Cash per Share (MRQ)
1.91CNYUpdated Sep 20, 2026Total Debt (MRQ)
972.57MCNY145.13M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.2865xvs Medical Devices peers
Current Ratio (MRQ)
1.23xvs Medical Devices peers
Book Value per Share (MRQ)
5.78CNYUpdated Sep 20, 2026Total Assets
5.96BCNY889.68M · vs all stocks (USD)
Total Current Assets
2.46BCNYFY2025 · Dec 31, 2025Total Liabilities
2.52BCNYFY2025 · Dec 31, 2025Total Non-current Assets
3.50BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
361.95MCNYFY2025 · Dec 31, 2025Total Current Liabilities
2.16BCNYFY2025 · Dec 31, 2025Cash
748.44MCNYFY2025 · Dec 31, 2025Cash Equivalents
30.62MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
779.06MCNYFY2025 · Dec 31, 2025Other Short-term Investments
244.35MCNYFY2025 · Dec 31, 2025Accounts Receivable
513.22MCNYFY2025 · Dec 31, 2025Inventory
760.18MCNYFY2025 · Dec 31, 2025Accounts Payable
361.40MCNYFY2025 · Dec 31, 2025Short-term Debt
625.20MCNYFY2025 · Dec 31, 2025Other Current Liabilities
224.25MCNYFY2025 · Dec 31, 2025Long-term Debt
203.63MCNYFY2025 · Dec 31, 2025Common Stock (Book)
560.27MCNYFY2025 · Dec 31, 2025Retained Earnings
1.07BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
3.44BCNY513.94M · vs all stocks (USD)
Treasury Stock
286.62MCNYFY2025 · Dec 31, 202552-Week Low
13.37CNYUpdated Sep 20, 202652-Week High
20.35CNYUpdated Sep 20, 202652-Week Change
-22.16%vs all stocks
Beta
-0.1220xvs all stocks
50-Day MA
15.90CNYUpdated Sep 20, 2026200-Day MA
16.44CNYUpdated Sep 20, 2026Avg 10-Day Volume
3.11MSharesUpdated Sep 20, 2026Avg 30-Day Volume
4.32MSharesUpdated Sep 20, 2026Diluted EPS (TTM)
0.2500CNYUpdated Sep 20, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Current ratio is 1.23×, lower than 95% of its Medical Devices peers (median 2.86×)Significant
Current ratio: 1.23Industry median: 2.86Industry P5: 1.31Peers compared: 60.00
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.54Profit Margin: 0.03
Financial Health
Altman Z-Score 3.23: safe zoneNotable
Altman Z-Score: 3.23
High earnings qualityNotable
Earnings Quality Score: 0.55
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Scale
Market cap is $1.3B, above the global median of $1.18BNotable
Market cap (USD): 1,298,736,465.031Global Median: 1,180,223,658.953
Revenue is $736.06M, above the global median of $548.88MNotable
Revenue (USD): 736,058,205.481Global Median: 548,883,780.48
Levered free cash flow is $55.94M, above the global median of $18.73MNotable
Levered free cash flow (USD): 55,936,251.072Global Median: 18,729,043.027
Companies that share the same coordination system — how they create, deliver, or capture value.
North China Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Hisun Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Bio-Thera Solutions Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Liaoning Chengda Biotechnology Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Shandong Weigao Orthopaedic Device Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Yizhong Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Akums Drugs & Pharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Damora Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jiangsu Yahong Meditech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule